Category: Our News

Challenge: The Chimeric Antibody Receptor (CAR) presents a promising avenue in cancer immunotherapy by engineering patients’ T cells to express CAR molecules, enabling targeted recognition and elimination of tumor cells. While CAR-T therapy has demonstrated notable success in inducing remission for B cell leukemia, lymphoma, and multiple myeloma, it has failed in non-hematologic solid tumors, with…

Challenge: Acute leukemia is the most common blood cancer in children. Aggressive chemotherapy and radiation treatments cure about 80% of affected children. However, they are not perfect cures since a part of children is incurable and dies of leukemia and these treatments kill not only the cancer cells, but also the healthy ones. As a result,…

Challenge: The knowledge gained in cancer immunology has increased the list of new therapeutic applications. Yet, these approaches (CAR-T, check-point inhibitors and others) are still suffering from several drawbacks, among them: very high cost, more complex biological or/and cellular-based technologies, lack of efficiency against solid tumours, difficulties in validating multiple combination therapies, increased difficulty in selection…

Challenge: Nerve blocks have revolutionized anesthesia and surgery as well as chronic pain management. They provide better pain relief, significantly reduce the need for opioids, thus impacting on the problem of opioid addiction, speed up recovery from surgery, as well as shorten hospital stay. However, they require special training as well as regular skills maintenance. Very…

Challenge: As the global SARS-CoV-2 situation continues to evolve, the strategy of focusing vaccine development on the currently dominant variant of concern (eg. BA.4 and BA.5 in 2022, XBB.1.5 in 2023) should be complemented by approaches that provide more durable and wider protection against future, emerging variants that can be quickly manufactured for urgent deployment. Solution: The…

Challenge: Vaccination has historically shown effectiveness in preventing morbidity caused by infectious diseases. Therefore, the notion of developing cancer vaccines remains appealing as a combinatory approach with the current standard of care. Unfortunately, a long list of vaccines tested so far has not been successful in achieving the hoped-for clinical outcome. As a result, the past…

Challenge: A need exists for new drugs efficiently targeting fungi such as Candida albicans, which affects thousands of patients on its own every year in Canada and over the world. Similarly, to antibiotics, fungi also show an increase in resistance against first-line therapeutic agents, including some that are considered as major treats to public health. Solution: The research…